AI Article Synopsis
- Combining low-dose tofacitinib with 308-nm excimer light therapy shows potential as a new treatment for patients with nonsegmental vitiligo.
- This combination therapy could be beneficial for those who haven't responded to traditional treatments.
- The findings suggest a promising option for better managing vitiligo symptoms in resistant cases.
Article Abstract
Combining low-dose tofacitinib with 308-nm excimer may be an effective treatment for patients with nonsegmental vitiligo who were refractory to conventional therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ced.15070 | DOI Listing |
Publication Analysis
Top Keywords
low-dose tofacitinib
8
tofacitinib 308-nm
8
308-nm excimer
8
excimer therapy
4
therapy induced
4
induced repigmentation
4
repigmentation patients
4
patients refractory
4
refractory vitiligo
4
vitiligo combining
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!